Re: Pembrolizumab Monotherapy for the Treatment of High-risk Non-muscle-invasive Bladder Cancer Unresponsive to BCG (KEYNOTE-057): An Open-label, Single-arm, Multicentre, Phase 2 Study. European urology Parikh, D. A., Khaki, A. R., Williams, S. B. 2022

View details for DOI 10.1016/j.eururo.2022.01.016

View details for PubMedID 35131115